Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -1.80% and Operating profit at -232.73% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 4.40% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -1.80% and Operating profit at -232.73% over the last 5 years
3
The company has declared negative results for the last 2 consecutive quarters
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,093 Million (Mid Cap)
NA (Loss Making)
NA
0.00%
0.26
-11.79%
3.64
Revenue and Profits:
Net Sales:
178 Million
(Quarterly Results - Sep 2025)
Net Profit:
-26 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.59%
0%
-12.59%
6 Months
25.36%
0%
25.36%
1 Year
34.62%
0%
34.62%
2 Years
50.86%
0%
50.86%
3 Years
-11.44%
0%
-11.44%
4 Years
-16.27%
0%
-16.27%
5 Years
36.87%
0%
36.87%
Chimin Health Management Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.80%
EBIT Growth (5y)
-232.73%
EBIT to Interest (avg)
0.94
Debt to EBITDA (avg)
6.88
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
0.39
Tax Ratio
14.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.98%
ROE (avg)
4.40%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.45
EV to EBIT
-47.62
EV to EBITDA
-334.97
EV to Capital Employed
3.77
EV to Sales
10.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-7.92%
ROE (Latest)
-9.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
178.30
181.30
-1.65%
Operating Profit (PBDIT) excl Other Income
-26.90
-9.90
-171.72%
Interest
6.20
5.80
6.90%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-25.70
-38.00
32.37%
Operating Profit Margin (Excl OI)
-151.10%
-217.80%
6.67%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -1.65% vs 1.63% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 32.37% vs -224.79% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
763.70
890.80
-14.27%
Operating Profit (PBDIT) excl Other Income
70.30
151.90
-53.72%
Interest
21.70
23.80
-8.82%
Exceptional Items
-1.60
-79.20
97.98%
Consolidate Net Profit
-56.10
-49.20
-14.02%
Operating Profit Margin (Excl OI)
-65.70%
47.50%
-11.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -14.27% vs 6.98% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -14.02% vs -288.51% in Dec 2023
About Chimin Health Management Co., Ltd. 
Chimin Health Management Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






